Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S100 calcium-binding protein A8 (S100A8) is a member of the S100 family of EF-hand calcium-binding proteins predominantly expressed in neutrophils and monocytes. It functions both intra- and extracellularly, mainly as a regulator and effector in inflammation and innate immune responses. S100A8 forms heterodimers (and higher-order complexes) with S100A9 (calprotectin), which are critical for chemotaxis, cytoskeletal reorganization, regulation of NADPH oxidase, and ROS production, as well as modulation of inflammatory signaling via receptors such as RAGE and TLR4. Its expression is elevated in a range of inflammatory and infectious diseases and certain cancers, and it serves as a biomarker for disease activity in several immune-mediated conditions. Structural studies show that it binds both calcium and zinc, which regulate its oligomerization and function[1][2][4][5][6][7].
Immune modulation; Inhibition of S100A8/A9–receptor interactions (e.g., TLR4, RAGE) to reduce inflammatory signaling[2][5]; Modulation of myeloid cell activity and migration
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S100 calcium-binding protein A8 (S100A8).